title: Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction.
abstract: It has been previously shown that regulators of physiological growth such as thyroid hormone (TH) can favorably remodel the post ischaemic myocardium. Here, we further explored whether this effect can be preserved in the presence of co-morbidities such as diabetes which accelerates cardiac remodeling and increases mortality after myocardial infarction. Acute myocardial infarction (AMI) was induced by left coronary ligation in rats with type I diabetes (DM) induced by streptozotocin administration (STZ; 35 mg/kg; i.p.) while sham-operated animals served as controls (SHAM). AMI resulted in distinct changes in cardiac function and geometry; EF% was significantly decreased in DM-AMI [37.9 ± 2.0 vs. 74.5 ± 2.1 in DM-SHAM]. Systolic and diastolic chamber dimensions were increased without concomitant increase in wall thickness and thus, wall tension index [WTI, the ratio of (Left Ventricular Internal Diameter at diastole)/2*(Posterior Wall thickness)], an index of wall stress, was found to be significantly increased in DM-AMI; 2.27 ± 0.08 versus 1.70 ± 0.05. 2D-Strain echocardiographic analysis showed reduced systolic radial strain in all segments, indicating increased loss of cardiac myocytes in the infarct related area and less compensatory hypertrophy in the viable segments. This response was accompanied by a marked decrease in the expression of TRα1 and TRβ1 receptors in the diabetic myocardium without changes in circulating T3 and T4. Accordingly, the expression of TH target genes related to cardiac contractility was altered; β-MHC and PKCα were significantly increased. TH (L-T4 and L-T3) administration prevented these changes and resulted in increased EF%, normal wall stress and increased systolic radial strain in all myocardial segments. Acute myocardial infarction in diabetic rats results in TH receptor down-regulation with important physiological consequences. TH treatment prevents this response and improves cardiac hemodynamics.
authors: Department of Pharmacology, University of Athens, 75 Mikras Asias Ave, 11527, Goudi, Athens, Greece.
authors: Christos
authors: C
authors: Kalofoutis
authors: Iordanis
authors: I
authors: Mourouzis
authors: Georgios
authors: G
authors: Galanopoulos
authors: Antonios
authors: A
authors: Dimopoulos
authors: Philippos
authors: P
authors: Perimenis
authors: Danai
authors: D
authors: Spanou
authors: Dennis V
authors: DV
authors: Cokkinos
authors: Jaipaul
authors: J
authors: Singh
authors: Constantinos
authors: C
authors: Pantos
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D015536:Down-Regulation / Q000235:genetics*; D018776:Genes, erbA; D009203:Myocardial Infarction / Q000473:pathology*; D051381:Rats; D011988:Receptors, Thyroid Hormone / Q000235:genetics*; D013963:Thyroid Hormones; D013974:Thyroxine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D014284:Triiodothyronine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D020257:Ventricular Remodeling / Q000235:genetics*
chemical_list: D011988:Receptors, Thyroid Hormone; D013963:Thyroid Hormones; D014284:Triiodothyronine; D013974:Thyroxine